Table 1.

Prevalence of HPV infection at baseline, irrespective of coinfections, vaccine and placebo arms combined

Women ages 15 to 26 yearsaWomen ages 24 to 34 yearsaWomen ages 35 to 45 yearsa
N = 17,590N = 1,911N = 1,908
HPV typen (%)n (%)n (%)
Any5,590 (33)564 (30)379 (20)
6716 (4)45 (2)26 (1)
11119 (1)7 (0.4)2 (0.1)
161,552 (9)116 (6)54 (3)
18642 (4)48 (3)31 (2)
31781 (4)59 (3)45 (2)
33358 (2)14 (1)13 (1)
35270 (2)30 (2)19 (1)
39798 (9)68 (4)44 (2)
45418 (2)40 (2)25 (1)
511,268 (7)90 (5)51 (3)
52984 (6)113 (6)57 (3)
561,336 (8)147 (8)92 (5)
58642 (4)61 (3)39 (2)
59641 (4)56 (3)28 (2)
Any of the nonvaccine high-risk types (35/39/51/56/59)
3,316 (19)318 (17)207 (11)
Any of the qHPV vaccine types (6/11/16/18)
259 (15)192 (10)106 (6)
Any of the 9vHPV vaccine types (6/11/16/18/31/33/45/52/58)
4,245 (25)375 (20)238 (13)
  • aThe denominator for each type analysis excludes subjects with missing data for the respective HPV type(s). The categories are not mutually exclusive.